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Abstract
Assessment of H1N1 vaccine effectiveness in preventing hospitalization in children
Felicity Lenes‐Voit, Alexandra P. Grizas, Novagrami George, Nancy Holabird,
Rebekah Stein and Marietta Vázquez. Department of Pediatrics. Yale School of
Medicine. New Haven, CT.
2013

In 2009, the first influenza epidemic of the new millennium emerged. H1N1
disproportionately infected, hospitalized and killed pediatric patients, but the bulk
of research on effective prevention was centered on the adult population. In order to
address this gap, we conducted a matched case‐control study to investigate the
effectiveness of H1N1 vaccination in preventing hospitalization due to influenza‐
related illness in children and adolescents aged 6 months to 17 years of age. We
found that one dose of H1N1 vaccine is only 30.5% effective in protecting against
hospitalization for H1N1 influenza and identified several risk factors for an
increased likelihood of hospitalization for influenza that can be used to guide future
immunization policy.
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CHAPTER 1

INTRODUCTION
1.1 Motivation
Three times in the last century, and for the first time during the new millennium
in 2009, a pandemic influenza strain emerged: H1N1. By altering the subtype of flu
virus that predominates globally, H1N1 exacted a large toll of morbidity and
mortality via the introduction of unfamiliar, mutated cell surface antigens, the
molecules that allow a host immune system to recognize and repel viral invaders.
Vaccines are crucial in preventing widespread epidemics of seasonal flu, which has
comparatively fewer differences from strains previously experienced by humans
than pandemic flu. Therefore, vaccines are even more important in containing
pandemics because they train the immune system to recognize and respond to novel
pathogenic threats, thereby enabling prevention of disease—when a vaccine is
effective‐‐ whereas otherwise the body would only have more limited defenses.
Similarities to previously circulating strains of influenza, a rapid response by the
healthcare community, and more advanced healthcare technologies for individuals
who contracted influenza and experienced influenza‐related complications,
restrained the morbidity and mortality of this pandemic in older adults. But in
children, lack of exposure to previous strains of H1N1 flu dealt a harsher hand and
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led to unusually high attack rates, hospitalizations and deaths. As we look to the
future, it is ever more critical that our prevention methods are effective, particularly
in children whose immune systems are less developed compared to adults, having
been exposed to a smaller number of immunologic threats. Accordingly, evaluation
of vaccine effectiveness in pediatric patients contributes significantly to our
preparedness for future pandemics by identifying gaps in effectiveness, which will
help save lives during subsequent outbreaks.
1.2 Influenza
Influenza, commonly called “the flu,” is a contagious respiratory illness caused
by influenza viruses, single‐stranded RNA viruses of the Orthomyxoviridae family,
which includes types A, B and C flu (1). Infections with the A or B types of this virus
are most common and can result in illness ranging from mild to severe with life‐
threatening complications, with severity correlated to which viral surface molecules
are expressed for Type A influenza. There is only one subtype of Influenza B,
although there are two lineages (2). However, Type A viruses express two variable
hallmark surface antigens: hemagglutinin and neuramidinase.
Hemagglutinins are antigenic glycoproteins that facilitate binding of the virus to
cells, cause red blood cell aggregation in vitro, and are the primary targets of host
immune systems. Glycoside hydrolase enzymes called neuraminidases allow
penetration through the respiratory tract mucosa and are a common antiviral target

2

(3). Seventeen hemagglutinins have been identified in human and avian influenza A
viruses, as well as 9 forms of influenza neuraminidase, leading to substantial
variation in the types of viruses that can cause disease. H1‐3 and N1 and N2 are far
more common in human strains of the flu virus, and worldwide pandemics have
thus far been caused by only four of the subtypes: H1N1, H1N2, H2N2 and H3N2
(1,4,5).
There is a particularly high rate of point mutation in the hemagglutinin gene,
which allows the virus to evade recognition by the host immune system via
antigenic drift – small evolutionary changes over time in response to selection
pressures. Less frequent, but more dramatic, is a phenomenon known as antigenic
shift, which is a reassortment of viral genomes due to either cross‐species
transmission or concurrent infection by multiple viruses in the same host which
leads to gene fracture and recombination (6,7). Type B viruses mutate much more
slowly and are therefore substantially less likely to cause pandemics, though they
occasionally cause epidemics. In addition to being classified by type, influenza
viruses are also subclassified according to the location and year they were first
isolated , for example A/California/2009 H1N1 (1,5).
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1.3 Epidemiology
Although each season is unique, the Centers for Disease Control and Prevention
(CDC) estimate that every year, 10% of U.S. residents contract influenza and
approximately 200,000 persons are hospitalized for flu‐related complications.
Nationally, the total annual mortality due to influenza ranges from 3,000‐49,000,
usually due to complications of the illness; mortality also tends to be much more
severe in years when an H3N2 virus predominates (8). The influenza viruses are
spread from person to person via respiratory droplets. On occasion, they are also
transferred species to species, mutating swiftly in the process. Several times per
century, strains sufficiently immunologically distinct emerge, eluding crossover
recognition by both B‐ and T‐cells, and resulting in pandemics (1).
There were three influenza pandemics during the 20th century: an H1N1 variant
in 1918 that is estimated to have cost more lives than the Great War, an H2N2 strain
in 1957, and a H3N2 strain in 1968 that predominated until recently (9,10,11). The
most recent pandemic influenza, 2009 H1N1, was notable not only because its death
toll of at least 30,000 Americans was over five times the expected mortality from an
H1N1 virus, but also because instead of preying most heavily on the elderly and
immunocompromised, it was particularly virulent in the young and in persons with
intact immune systems. Consistent with previous pandemics, it is likely that 2009
H1N1’s much higher attack rates, mortality rates, and hospitalization rates in young

4

children and adolescents than what is typically observed with seasonal flu was due
to an epidemiologic shift in the susceptible population because older adults had
been previously exposed to H1N1 strains, which provided protection through
antibody production with a residual memory effect (1, 5, 12, 13, 56).
Sixty percent of H1N1 cases occurred in children or adolescents under the age of
18 (14). In contrast to the seasonal flu trend of influenza‐associated deaths
occurring almost exclusively in individuals >65 years, 2009 H1N1 claimed more
than 90%of its mortalities in persons <65 years (15), and ten times as many
pediatric victims as seasonal flu in the preceding years (16). Pandemic 2009 H1N1
influenza is a type A influenza virus first diagnosed in the United States in April
2009 after being identified in Mexico as causing an outbreak of respiratory illness
(17). Within weeks, it had spread across North America and in June 2009, the World
Health Organization (WHO) upgraded the novel influenza virus to a Grade 6 alert,
signifying it had become a global pandemic (9,18). Its emergence substantially
altered the predominant subtypes of flu since the 1970s from >90% H3N2 globally
to >98% H1N1 as of the 2011‐2012 influenza season (see Figure 2) (6, 19).
Seropositivity studies suggest that more than 20% of the US population, and 53% of
U.S. children aged 5‐17, had been infected with H1N1 by December 2009 (20).
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1.4 Prevention Techniques
The best prevention against influenza infection is annual vaccination, which
several large retrospective cohort studies have found to be protective against all‐
cause mortality (21, 22, 23). The CDC recommends that all children and adolescents
be vaccinated with influenza vaccine as a protective measure against flu‐related
disease. For children from 6 months to nine years of age, the first time a vaccinee is
immunized against influenza, it is recommended to receive two doses at least one
month apart.
Some of the more serious complications caused by influenza include bacterial
pneumonia, dehydration, and worsening of chronic medical conditions, such as
congestive heart failure, asthma, or diabetes. Children may also develop sinus
problems, ear infections and gastrointestinal distress (1). Although it is more
difficult to measure health care demands associated with influenza infections not
requiring hospitalization, Neuzil et al found, on average, a fifteen percent increase in
outpatient provider visits, and a 3‐9 percent increase in (unnecessary) antibiotic
prescriptions for patients ultimately found to have the flu (24). Since children shed
live virus for longer periods of time than adults, they function as a riskier vector
population, which makes prevention particularly cost‐effective among this group
(25). Since vaccination is the best and most cost‐effective prevention strategy for
influenza—savings are estimated between $8,000 and $52,000 per successful
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immunization—investigating the effectiveness of the H1N1 vaccine in this age group
is particularly relevant to global public health efforts (26, 27).
Unfortunately, inactivated influenza virus vaccine is poorly immunogenic in
children younger than six months of age and is not approved for children in this age
group, even though children < 6 months of age are at highest risk for influenza‐
related complications (28). A promising study addressing this issue found that
vaccinating pregnant mothers protects their infants until the children are of age to
be safely and effectively vaccinated themselves (57). Another strategy is to employ
cocooning by vaccinating individuals who may potentially transmit the influenza
virus to a susceptible neonate or infant (58).
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1.5 Vaccine Effectiveness
In mid‐October 2009, H1N1 vaccine became available only to priority groups in
the United States due to limited supplies (29). Priority vaccines included pregnant
women, household contacts of children younger than six months of age, healthcare
workers, children and young adults aged six months to 24 years, and persons aged
25‐64 with chronic medical conditions increasing their risk of complications from
influenza. The bulk of influenza vaccines are grown on chicken eggs, so supply is
constrained and resources had to be diverted from seasonal flu vaccine production
to pandemic vaccine production (30). CDC recommendations for initial influenza
immunization in children dictate receiving two doses spaced one month apart, and
early predictions were that the H1N1 vaccine would require two doses for all
vaccines in order to confer immunity to H1N1 influenza. However, a study published
in September 2009 in the New England Journal of Medicine suggested that one dose
would be sufficient, effectively doubling the number of doses available to the
population (5). This early study only assessed immunization of adults and
concluded that due to well‐documented differences in the immune response of
children, further research was needed. The priority list for the limited initial supply
of vaccine included children and adolescents between the ages of 6 months and 24
years of age (rather than individuals over age 65) in response to observations that
previous cases of H1N1 influenza had caused more serious complications in this age
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group. Children and adults were administered the vaccine although little data on
efficacy were available.
While subsequent studies have shown good efficacy of the live attenuated
vaccine in provoking an adequate immune response as measured by antigen‐
antibody titers when adjuvanted (5), the United States has not yet licensed
adjuvanted influenza vaccines (1, 27, 31). Non‐adjuvanted preparations are not
equally efficacious at stimulating a measurable immune response indicated by a
>40:1 antibody titer (12). And even if a vaccine in efficacious, that does not
necessarily mean it will be effective, as measured by preventing clinical disease.
There have been conflicting reports on the effectiveness of the vaccine in preventing
clinically significant flu, with several studies finding that the vaccine is effective in
this age group being funded or conducted by vaccine manufacturers and using
adjuvants not otherwise available (32, 33). The ability to mount a measurable
immune response has been found to vary by age, with a significantly smaller
proportion of 3‐11 year olds (younger children were not studied) mounting
satisfactory hemagglutinin‐inhibition titers than individuals >12 years of age after
one dose of both alum‐adjuvanted and unadjuvanted vaccines (34). One study
published in Lancet in 2010 found that fewer than half of children under the 3 years
of age mounted a protective antibody titer to one dose of the non‐adjuvated live
attenuated vaccine licensed in the United States (35). Despite this evidence of a lack
of measurable immunoprotection from the licensed vaccine after one dose, and the
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longstanding CDC recommendation for children to receive two doses of influenza
vaccine, in practice few children receive both doses. Therefore, continued evaluation
of the clinical effectiveness of the US‐licensed unadjuvanted vaccine – showing that
not only does the vaccine not stimulate a protective immune response, but that this
lack of efficacy also decreases the unadjuvanted vaccine’s effectiveness at
preventing hospitalizations for influenza – is crucial to public health efforts to alter
policy in order to provide the vulnerable pediatric population with effective
vaccination coverage – either by increasing efforts to ensure children complete both
doses, or by licensing adjuvanted vaccines that are effective at lower and fewer
doses – and to help guide vaccination efforts during future seasons and similar
pandemics.
The effectiveness of attenuated viral vaccines in preventing disease depends not
only on the age and immunocompetence of the vaccine recipient, but also on the
degree of similarity between the viruses in the vaccine and those in circulation (1).
The majority of vaccinated children and young adults develop high post‐vaccination
antibody titers that are protective against illness caused by strains similar to those
in the vaccine, although attaining a particular titer level is not absolutely
correspondent to immunity and does not translate directly to a measure of a
vaccine’s effectiveness (31). Children aged as young as 6 months can develop
protective levels of antibody after influenza vaccination, although the antibody
response among children at high risk of influenza‐related complications might be
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lower than among healthy children (36, 37). Recommendation to give influenza
vaccine routinely to children over the age of 6 months is based on an assumption
that influenza vaccine will be as effective in preventing hospitalization in these
children as it is in the elderly. However, it may not be reasonable to assume that
influenza vaccine is as efficacious or effective in these children, especially because
existing immunological data suggests a less robust immune response to typical
vaccine doses in individuals younger than twelve years of age (34). The safety of the
pandemic H1N1 influenza vaccine in children and adolescents has been established,
but it is still not clear what immunization schedule is necessary for effective
vaccination against H1N1 influenza with the licensed unadjuvanted vaccine (38, 39).
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1.6 Hypothesis
H1N1 vaccine is effective in preventing hospitalization due to H1N1 influenza‐
related illness in a pediatric population.
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CHAPTER 2
MATERIALS AND METHODS

2.1 Matched Casecontrol Study
Thesis writer Felicity Lenes‐Voit designed the study in conjunction with and
under the guidance of Dr. Vázquez, conducted all of the medical records reviews,
helped to (but did not primarily) identify case and control subjects, interview and
consent them and add their information to the database. She checked data in the
database and conducted statistical analysis with SAS code written by Alexandra
Grizas and edited by Emily Bucholz, as well as conducting a literature review and
writing this manuscript.
A matched case‐control study was developed to study the effectiveness of H1N1
vaccine in preventing hospitalization due to laboratory‐confirmed H1N1 influenza
in children. Potential subjects were identified retrospectively for the 2009‐2010 flu
season using the existing hospital infectious disease virology surveillance tool, then
enrolled prospectively for the 2010‐2011 and 2011‐2012 seasons. Cases were
identified in one of the following ways:
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1. From an existing active surveillance program conducted by the Connecticut
Emerging Infections Program at Yale (EIP: Multi‐state Population Based
surveillance for Influenza‐Associated Hospitalizations in Children). This
surveillance includes all children admitted to Yale‐New Haven Hospital
(YNHH), an urban academic hospital in the Northeastern United States, due
to influenza and has been in place since 2003.
2. From the daily list of pediatric admissions to YNHH. This list is compiled by
the admitting resident in Pediatrics.
3. Via surveillance of respiratory specimens submitted to the clinical virology
laboratory from children and adolescents hospitalized at YNHH. Policy at
YNHH dictates that all children or adolescents with respiratory complaints
of symptoms during flu season have a specimen sent to virology for analysis.
4. From data from YNHH’s infection control surveillance for influenza—
conducted routinely at YNHH every influenza season.
2.2 Case Subject Definition
A case subject was defined as a child aged 6 months to 17 years who was
hospitalized at Yale‐New Haven Hospital (YNHH) due to or with a diagnosis of H1N1
novel influenza tested by Direct Fluorescence Antibody (DFA) test and confirmed as
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novel H1N1 by RT‐PCR lab tests any time between November 1, 2009 and May
2012. This interval began two weeks after the H1N1 vaccine became available to
account for the lag time necessary to mount an immune response to a vaccine. The
age of 6 months was chosen because that is the minimum recommended age for the
vaccine owing to immunological development in infants.
Prospective cases provided a nasal wash for laboratory testing if their influenza
had not already been typed by the hospital’s clinical virology laboratory.
Medical records of identified case‐subjects were reviewed to collect
demographic information including race and ethnicity and to confirm that clinical
symptoms at time of diagnosis were consistent with influenza (the combination of
fever, respiratory difficulty, and cough within 48 hours of development of symptoms
is a validated multivariate predictor). The medical records of the case subjects were
also reviewed to gather necessary information to complete a validated influenza
clinical severity score that assessed heart rate, respiratory rate, oxygen saturation,
signs of difficulty breathing (including wheezing, retractions, nasal flaring), whether
mechanical intubation was required, whether the patient’s condition merited
admission to the intensive care unit (ICU), and whether or not there was a
documented abnormal chest radiograph. We obtained informed consent and
conducted interviews to obtain information related to disease processes, household
statistics, and demographics. Otherwise eligible subjects were excluded if they were
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immunocompromised or informed consent could not be obtained. Nosocomial
infections were also excluded.

2.2 Control Subjects
Control subjects were children matched on admit date (+/‐ 14 days of case
admission) and date of birth (+/‐ 28 days for subjects >6 months ‐<5 years; +/‐ one
year for patients 5 ‐<18 years) to case subjects. Put another way, control subjects
were patients hospitalized with non‐respiratory complaints at YNHH of similar age
as their matched case subjects and admitted within two weeks of their matched case
subject who did NOT have positive RT‐PCR for H1N1. At least two matched controls
were recruited per case, with up to seven matched controls. Controls were also
excluded if they were immunocompromised or informed consent could not be
obtained.

2.3 Informed Consent
Written informed consent was obtained from all study subjects. Participants
completed a short questionnaire by phone providing information about items
deemed to be possible confounders, such as comorbid health conditions, living
conditions, day care or school attendance, second hand smoke exposure, household
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size and vaccination status. Vaccination status was confirmed from healthcare
provider records. Study subjects were considered vaccinated if they had received a
documented dose of H1N1 influenza vaccine 14 or more days prior to hospital
admission.

2.4 Data Management and Statistical Analysis
A database was created in Microsoft Access. Data were entered twice and
multiple data checks were done to correct and check errors. Data were exported to
Microsoft Excel for statistical analysis in the SAS statistical programs for personal
computers [SAS® for Personal Computers. SAS Institute, Inc., Cary, NC: 1999,
version 9.2] The protective efficacy (PE) of a vaccine, which is the proportional
reduction in the risk of infection among vaccinees that is attributable to the vaccine,
is calculated with data from clinical trials as:
PE = risk of infection in controls ‐ risk of infection in vaccines
risk of infection in controls

This equation reduces to:
1 ‐ risk of infection in vaccinees or 1 ‐ the relative risk.
risk of infection in controls
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For case‐control studies, the standard measure of association is the odds ratio.
We performed a matched analysis, since the controls were matched individually to
the cases based on date of birth and date of hospitalization, with at least two and up
to seven controls per case. Since for this type of study the matched odds ratio closely
approximates the relative risk that would be observed in a prospective
interventional clinical trial, the matched odds ratio can be substituted for the
relative risk in the above equation and the vaccine's protective efficacy is estimated
as: 1 ‐ the matched odds ratio.
Matched odds ratios, with both their associated statistical significance (assessed
with the Mantel‐Haenszel χ2 for matched triplets) and their 95% confidence
intervals were calculated with the use of conventional techniques. In addition,
conditional logistic regression was used to adjust these estimates.
A 30 percent vaccine coverage rate was used to construct the statistical models
because the CDC and Committee on Infectious Disease estimated 32 percent
coverage (26, 40). It is not clear from existing research precisely what percentage of
coverage is required to establish herd immunity, with computer models predicting
from 80‐98% (45). Loeb et al. have demonstrated that it is possible to induce herd
immunity to flu in small communities using the inactivated vaccine (46) but
different yearly strains and vaccines of varying effectiveness present different
coverage demands to reduce outbreaks through the herd effect.
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Table 1
Power calculations
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CHAPTER 3
RESULTS
3.1 Case and control identification
We identified 85 case subjects, 79 of which were retrospective and 6 of which were
prospective. One of the prospective cases resided out of state and was lost to follow
up. Nine retrospective cases refused to be interviewed, one refused to sign consent,
five were ineligible (3 hospitalized for non‐respiratory complaint with influenza an
incidental finding, 1 admitted for a nosocomial infection and one resided out of
state.) 16 were not able to be contacted. 47 were interviewed and consented, with
medical record reviews completed. We then obtained their vaccination records for
45 patients from their healthcare providers. Of the 755 identified possible age‐ and
date of admission‐matched controls, 175 were interviewed; 124 gave consent; 25
refused to be interviewed; 2 were excluded and 140 medical record reviews were
completed for documentation of vaccinations. The remaining identified possible
control subjects have not been able to be contacted currently.
3.2 Demographics
Of the case subjects, 57.8% were female and 46.2% were male, while the control
subjects were 48.5% female and 51.5% male. 22.2% of the case subjects were two
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years of age or younger, whereas in the control population, 17.5% were two or
under. 42.2% of the case subjects were non‐Hispanic white; 31.1% were Hispanic;
26.7% were black or other non‐white race. The control subjects were 74.2% white,
16.5% Hispanic and 9.3% black or other non‐white race. 52.3% of the case subjects
were breastfed, while 66% of the control subjects were breastfed. Our data shows
significant associations between hospitalization for influenza and lower parental
education. Families in which one or both parents were college graduates had a
lower rate of hospitalization for influenza. In our study, 40% of the children
hospitalized due to H1N1 had parents or caregivers who were college graduates,
while 58.5% of control subjects were cared for by college graduates. This difference
was statistically significant (p=0.049). Having a lower household income was also
significantly associated with an increased likelihood of being hospitalized with
H1N1, with 58.8% of case subjects living in households making less than $30,000
per year, but only 35.7% of control subjects living in low‐income households
(p=0.021). Preterm birth was not found to be a significant predictor of likelihood
for hospitalization with H1N1 influenza, with 18.6% of the case subjects born before
term and 14.7% of control subjects delivered early. There was also no significant
difference between case and control groups in regards to school or daycare
attendance, with 75% of case subjects attending school or daycare and 80.4% of
control subjects attending school or daycare. Respiratory comorbidities were found
to be correlated with a higher rate of influenza severe enough to warrant
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hospitalization, with 52.3% of the case subjects reporting a respiratory comorbidity
and 32% of control subjects. The severity of respiratory comorbidities was
consistent across groups. Other comorbidities did not affect the likelihood of
hospitalization for influenza, with 54.5% of case subjects with a non‐respiratory
comorbidity and 42.1% of control subjects. 22.2% of case subjects were only
children, whereas 24.7% of control subjects had no siblings. Regarding housing
arrangements, 20% of case subjects lived in single family dwellings or duplexes
whereas 80% lived in multiple family dwellings like apartments. Among control
subjects, 26% lived in stand‐along housing. Vaccination status was not significantly
different between those with and without influenza, with 11.1% of the case subjects
being vaccinated and 19.6% of the control subjects.
3.3 Vaccination Status
There were several demographic characteristics that predicted vaccination with at
least one dose of live attenuated H1N1 influenza vaccine in our sample. Younger
children under the age of two were statistically significantly more likely to be
vaccinated than older children, with 41.7% of those who were vaccinated two years
of age or under, and only 14.4% of the unvaccinated study subjects two or younger.
(p=0.002). 41.7% of the study subjects who were vaccinated were female, whereas
53.4% of the unvaccinated were female. 66.7% of those vaccinated were white,
20.8% were black or other non‐white race. 12.5% were Hispanic. Of the
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unvaccinated, 63.5% self‐identified as white, 12.7% as black or other non‐white
race, and 22.8% as Hispanic. 62.5% of the vaccinated were breastfed, whereas
61.4% of the unvaccinated were breastfed by caregiver report. Of those study
subjects whose caregivers were college graduates, there was no statistical difference
in likelihood to be vaccinated, with 56.5% of vaccinated study subjects having a
parent or caregiver with a college degree, and 52.3% of the unvaccinated. Higher
household income did not increase statistical likelihood to vaccinate either: 65.2%
of study participants who were vaccinated lived in households with annual income
exceeding $30,000, whereas 55.8% of the unvaccinated study subjects lived in these
households. Preterm birth narrowly missed statistical significance as a predictor of
vaccination status. 29.2% of the vaccinated were preterm, whereas 13.2% of the
unvaccinated were delivered before term. Similar percentages of individuals
attended daycare and/or school among both the vaccinated (66.7%) and
unvaccinated (81.2%). 37.5% of vaccinees had a respiratory comorbidity reported
in their medical records, but that did not differ from the unvaccinated, 38.5% of
whom carried diagnoses of comorbid respiratory conditions. There was also no
difference between the vaccinated (50%) and unvaccinated (45.2%) in terms of
incidence of other comorbidities. 29.2% of the vaccinated were only children, and
22.9% of the unvaccinated had no siblings. As for housing arrangements, 37.5 of the
vaccinated lived in stand‐alone single‐family homes or duplexes, compared to
22.0% of the unvaccinated.
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In the univariate, matched bivariate and multivariate analyses, vaccination
status was not associated with a lower likelihood to be hospitalized for influenza
(see tables 1, 3, 4 and 5). In the matched conditional logistic regression, respiratory
comorbidities, non‐White race and household income <$30,000 annually each bore
odds ratios indicating an increased risk for hospitalization with H1N1 in our sample.
However, in the multivariate analysis, none of these factors were independently
significant. The odds ratio for the matched, adjusted multivariate analysis
comparing vaccination status with likelihood to be hospitalized due to H1N1
influenza crossed one, but would yield a vaccine protective efficacy of only 30.5%.
(1‐0.695).
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Table 2
Comparison of case subjects hospitalized with laboratory proven H1N1 versus matched case
controls hospitalized with non-respiratory complaints

Patients hospitalized with laboratoryproven H1N1
Variable
(N=142)
Age at Hospitalization*
> 2 years
≤ 2 years
Gender
Female
Male
┴*
Race/Ethnicity
Hispanic
Black/other non-white
White
Breastfed (self-reported)
Yes
No
Caregiver education
College graduate
Some college or less
Household income
> $30K
< $30K
Preterm
Yes
No
School/daycare attendance
Yes
No
Respiratory comorbidity
Yes
No
Other comorbidity
Yes
No
Siblings
0
+1
Housing
Single family/duplex
Multifamily (items 3-8)
Vaccinated
1+ doses vaccine
0 doses

b

Yes
45 (%)

No
97 (%)

35 (77.8)
10 (22.2)

80 (82.5)
17 (17.5)

26 (57.8)
19 (46.2)

47 (48.5)
50 (51.5)

14 (31.1)
12 (26.7)
19 (42.2)

16 (16.5)
9 (9.3)
72 (74.2)

23 (52.3)
21 (47.7)

62 (66.0)
32 (34.0)

16 (40.0)
24 (60.0)

55 (58.5)
39 (41.5)

14 (41.2)
20 (58.8)

54 (64.3)
30 (35.7)

8 (18.6)
35 (81.4)

14 (14.7)
81 (85.7)

33 (75.0)
11 (25.0)

78 (80.4)
19 (19.6)

23 (52.3)
21 (47.7)

31 (32.0)
66 (68.0)

24 (54.5)
20 (45.5)

40 (42.1)
55 (57.9)

10 (22.2)
35 (77.8)

24 (24.7)
73 (75.3)

9 (20.0)
36 (80.0)

26 (26.8)
71 (73.2)

5 (11.1)
40 (88.9)

19 (19.6)
78 (80.4)

p-value
0.507

0.301

0.002

0.124

0.049

0.021

0.565

0.467

0.022

0.171

0.744

0.381

0.210
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Table 2 Footnotes
a

Column values are n (column %). May not sum to 100% due to rounding and/or missing data.

b

Includes only study eligible subjects as described in Materials and Methods.

* Statistically significant at the α = 0.05 level for chi‐square test for categorical variables and t‐
test or Wilcoxan Rank Sum test for continuous variables.
┴

Other includes multiracial, other race, Asian, American Indian, Native Hawaiian/Pacific Islander.

Other, Black, and White are all non‐Hispanic
 Other comorbidities include sickle cell disease, renal disease, heart problems, immune
deficiencies, birth defects, spinal cord injury, epilepsy, mental retardation, neurologic or
neuromuscular diseases, metabolic or endocrine diseases, other chronic illnesses.
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Table 3
Comparison of vaccinated and unvaccinated study subjects

Comparison by Vaccination Status
Variable
(N=142)
Age at Hospitalization*
> 2 years
≤ 2 years
Gender
Female
Male
Race/Ethnicity
White
Black or other
Hispanic
Breastfed (self-reported)
Yes
No
Caregiver education
College graduate
Some college or less
Household income
>$30K
<$30K
Preterm
Yes
No
School/daycare attendance
Yes
No
Respiratory comorbidity
Yes
No
Other comorbidity
Yes
No
Siblings
0
1+
Housing
Single family/duplex
Multifamily (items 3-8)

Vaccinated
24 (%)

b

Not
vaccinated
118 (%)

p-value
0.002

14 (58.3)
10 (41.7)

101 (85.6)
17 (14.4)

10 (41.7)
14 (58.3)

63 (53.4)
55 (46.6)

16 (66.7)
5 (20.8)
3 (12.5)

75 (63.5)
15 (12.7)
27 (22.8)

15 (62.5)
9 (37.5)

70 (61.4)
44 (38.6)

13 (56.5)
10 (43.5)

58 (52.3)
53 (47.7)

15 (65.2)
8 (34.8)

53 (55.8)
42 (44.2)

7 (29.2)
17 (70.8)

15 (13.2)
99 (86.8)

16 (66.7)
8 (33.3)

95 (81.2)
22 (18.8)

9 (37.5)
15 (62.5)

45 (38.5)
72 (61.5)

12 (50.0)
12 (50.0)

52 (45.2)
63 (54.8)

7 (29.2)
17 (70.8)

27 (22.9)
91 (77.1)

9 (37.5)
15 (62.5)

26 (22.0)
92 (78.0)

0.295

0.443

0.920

0.709

0.412

0.052

0.113

0.930

0.669

0.512

0.109
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Table 3 Footnotes
a

Column values are n (column %). May not sum to 100% due to rounding and/or missing data.

b

Received 1 or more doses of non‐adjuvanted nasal or live attenuated vaccine >14 days before

hospital admission.
* Statistically significant at the α = 0.05 level for chi‐square test for categorical variables and t‐
test or Wilcoxan Rank Sum test for continuous variables.
┴

Other includes multiracial, other race, Asian, American Indian, Native Hawaiian/Pacific Islander.

Other, Black, and White are all non‐Hispanic
 Other comorbidities include sickle cell disease, renal disease, heart problems, immune
deficiencies, birth defects, spinal cord injury, epilepsy, mental retardation, neurologic or
neuromuscular diseases, metabolic or endocrine diseases, other chronic illnesses.
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Table 4
Matched conditional logistic regression
Bivariate analysis with Odds Ratio predicting likelihood to be hospitalized for influenza

Variable
Female gender
Breastfed
Preterm
Respiratory Comorbidities
Other comorbidities
Nonwhite race
Hispanic ethnicity
Vaccinated
Caregiver graduated college
Income >30K
Siblings
Housing (apartment, multi‐
family)

Odds Ratio

N

0.679 (0.319‐1.454)
0.608 (0.297‐1.244)
1.344 (0.516‐3.497)

138
138
141

2.743 (1.2296.119)
1.949 (0.860‐4.419)
5.511 (1.481
20.508)
2.074 (0.879‐4.891)
0.408 (0.126‐1.319)
0.479 (0.222‐1.033)

139
111

0.375 (0.1450.970)
1.189 (0.445‐3.178)

142
142

1.534 (0.603‐3.900)

92

141
142
134
118

Table 5
Multivariate Odds Ratio predicting likelihood to be hospitalized due to H1N1
Controlled for Respiratory Comorbidity, non-white race and income.

Variable
Vaccination
Respiratory Comorbidity
Non‐White race
Income >30K
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Odds Ratio

N

3.327 (0.607‐18.242)
5.705 (0.897‐36.274)
5.515 (0.329‐92.446)
0.259 (0.013‐5.201)

120
120
120
120

Table 6
Adjusted Matched Multivariate Analysis with Odds Ratio of Vaccination status for H1N1
influenza versus hospitalization due to laboratory-confirmed H1N1 influenza

Vaccination Status versus hospitalization for influenza
Variable
(N=120)
Hospitalization Diagnosis
H1N1 influenza (case subject)
Non-respiratory (control subject)

Vaccinated
(%)

b

Not
vaccinated
(%)

p-value
0.374

22 (33.3)
44 (41.7)

15 (27.8)
39 (72.2)
Odds Ratio:
0.695
(0.645-3.218)
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CHAPTER 4
DISCUSSION

Vaccination with one dose of unadjuvanted H1N1 vaccine was only 30.5%
protective against hospitalization for H1N1 influenza‐related illness in our sample.
Existing immunological research suggests there is an age‐related difference in the
ability to mount a robust response to vaccine antigen required for effective
immunization (34, 35, 48, 50), and that even older children and adolescents—
despite their more competent immune systems compared to younger children—
have lower baseline protection from cross‐reactive antibodies due to lack of
exposure to previously circulating H1N1 subtype influenza viruses (1, 19, 40, 55).
Effectiveness studies and long‐term immunogenicity studies that found an influenza
vaccine effectiveness of >80% in young children and adolescents, or persistently
elevated protective antibody titers, were conducted using vaccines with adjuvants
(33, 41, 52), which are not licensed for flu vaccines in the United States (1, 36).
Further, head‐to‐head studies of adjuvanted flu vaccines versus conventional
vaccines have found markedly poorer results in the unadjuvanted vaccines in
achieving a protective antibody titer (>1:40) (42). In 2011, The World Health
Organization in its Seventh Meeting on Evaluation of Pandemic Influenza Vaccines in
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Clinical Trials explicitly stated that unadjuvanted vaccines and very‐low dose
adjuvanted vaccines were not capable of eliciting reliable seroprotection in children
(17).
Adjuvanted vaccines have suffered a poor public relations image secondary to
concerns that vaccine preservatives such as thimerosal and other additives
including MF59 and AS03 adjuvants, lead to an increased risk of autism in children
despite lack of scientific evidence to support this claim. It is possible that the strong
lobbying efforts by anti‐vaccine groups involved in vaccinations has resulted in
adjuvants not being embraced for influenza vaccines in the United States despite
their proven value in producing highly effective vaccines. With every vaccine
administration, there is a risk‐reward ratio – and adjuvants are perceived to
contribute substantial risk without commensurate reward, when the evidence
points to the opposite being true. In fact, safety studies have not thus far shown
statistical differences in side effects or serious events in conventional versus
adjuvanted vaccines (39, 43, 44) or in multiple doses of vaccine (38), rendering
safety concerns about vaccine adjuvants without teeth.
Since we found that one dose of unadjuvanted H1N1 influenza vaccine is not
highly protective in young children, possible solutions include bolstering current
recommendations for young children to receive a second dose (up to nine years old
with certain preparations according to immunological research) (39), a higher
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initial dose of antigen (47), and/or introducing adjuvanted vaccines for influenza.
These options taken together or separately could serve to reduce the toll on the
healthcare system currently observed due to influenza related illnesses, as well as
enable a better risk‐reward profile to vaccination. Additionally, research shows that
consumers of influenza vaccines, or in the case of pediatric patients, their parents,
have diminished safety concerns with each subsequent vaccination, and they are
overall more likely to be vaccinated subsequently once they have been initiated into
receiving influenza vaccinations (49, 52).
Other areas of improvement identified by our research include issues of
disparity. Individuals of lower socioeconomic status and minority status are at
greater risk of hospitalization from influenza, and should be priority targets for
effective vaccination programs. Given the average savings to the healthcare
apparatus of an average of $8‐52,000 per flu hospitalization prevented (26, 53), it
would be a sound policy choice to subsidize influenza vaccines for individuals not
able to afford them.
It does appear that certain high‐risk patients are being targeted for
immunization, as the younger children in our study were significantly more likely to
be vaccinated than those over the age of two. Especially vulnerable groups such as
children and adolescents with respiratory comorbidities including asthma were
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disproportionately hospitalized for influenza complications in our sample, and
would receive particular benefit from effective prevention strategies.
Our study did have some weaknesses. Although we computed a provisional vaccine
efficacy based on our data, we were not powered to detect such a small protective
effectiveness of the vaccine because we designed our study based on published data
from previous influenza vaccines for seasonal influenza which are typically in excess
of 80% effective in preventing influenza infection. Therefore, with a larger sample
size we might detect a different vaccine efficacy. Future research in partnership
with the Connecticut Children’s Medical Center to combine sample sizes may further
elucidate this issue, and will likely alter the protective efficacy of the vaccine in our
sample. Since we were adequately powered to detect an 80% protective effect of the
H1N1 vaccine in preventing hospitalization due to influenza in pediatric patients,
we do know that it is <80% effective and that further study is warranted to help
articulate vaccine policy and promote effective vaccine preparations and vaccine
dosing regimens in order to encourage responsible and prudent use of preventative
healthcare resources.
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